News | July 06, 2022
CEPI and Codiak BioSciences partner to develop protective Betacoronavirus vaccine
CEPI will provide seed funding of up to US$2.5 million to Codiak BioSciences.
CEPI will provide seed funding of up to US$2.5 million to Codiak BioSciences.
Submission seeks approval for the treatment of COVID-19 in both vaccinated and unvaccinated individuals at high risk
This multicenter, open-label Phase I study is designed to assess the safety and tolerability
First and only PARP inhibitor to improve invasive disease-free survival in patients
The FDA informed Astellas that it did not have sufficient information to assess the risks to subjects
This includes USD 100 million to advance R&D of its neglected tropical disease program, focusing on novel drug candidates for four diseases.
Dr. Rizo brings extensive industry leadership experience to Vividion, having held multiple senior executive roles during her career at both biotechnology and large pharmaceutical companies.
V116 designed to target serotypes that account for 85% of all invasive pneumococcal disease in individuals aged 65 and over in the United States as of 2019
LYNPARZA is approved in the U.S. for patients with HRR gene-mutated mCRPC (BRCA-mutated and other HRR gene mutations)
Ganguly will execute company's strategic focus on leveraging CustomGlycan to develop novel therapeutics
Subscribe To Our Newsletter & Stay Updated
